Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs.

Front Cell Dev Biol · 2025 · PMC12540542 · PMID 41133214

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Regarding OS, although the data are not yet mature, a clear trend of benefit has been observed in the disitamab vedotin group, with median OS not yet reached versus 25.92 months in the control group ( Qu et al., 2024 ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.